Post-earnings recap
Reported
Thu, May 7, 2026
EPS actual
$1.63
EPS est.
$0.98
EPS surprise
+66.84%
1-day move
-9.55%
Ligand Pharmaceuticals reported earnings that missed expectations on EPS, which likely contributed to the stock's significant decline of 9.55%. The lack of revenue data and guidance may have added to investor uncertainty. Overall, the results indicate challenges in meeting market expectations.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.63 | $1.84 | -11.4% |
| Revenue | N/A | $59M | N/A |
No transcript is on record, and the analysis is based solely on numerical results.
Ligand Pharmaceuticals Incorporated (LGND) operates in the health care sector, focusing on developing and commercializing technologies that enhance drug discovery and development. With a market cap of $5 billion, the company plays a crucial role in the pharmaceutical industry by providing innovative solutions that can potentially improve patient outcomes and drive growth in the sector.
Last quarter
In Q4-2025, Ligand Pharmaceuticals reported an impressive EPS of $2.02, significantly surpassing analyst expectations. The stock reacted positively, gaining 2.50% the following day.
Management promises and guidance
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+288.65%
Avg 1-day reaction
+1.63%
Analysts are generally optimistic about Ligand's upcoming earnings, expecting solid performance based on historical trends of exceeding EPS estimates. However, there is caution due to the potential for revenue fluctuations.
Bull case
If Ligand beats EPS expectations again, it could reinforce investor confidence and lead to a significant stock price increase, continuing the trend of positive market reactions.
Bear case
Conversely, if the company fails to meet revenue expectations, it could raise concerns about growth sustainability, leading to a negative market reaction.
Key metrics to watch
EPS
$1.84Earnings per share is a key indicator of profitability and will help gauge how well the company is managing its costs and generating revenue.
Revenue
$59MTotal revenue gives insight into the company's sales performance and market demand for its products and services.
The print will turn on these.
Q1
Will EPS exceed the consensus estimate of $1.84?
Given Ligand's strong history of beating EPS estimates, this will be a critical indicator of ongoing profitability and market confidence.
Q2
What will the revenue figure be compared to the consensus of $59M?
Revenue performance is crucial for assessing the company's growth trajectory and market demand for its products.
—
Est. EPS
$-0.76
Est. Rev
$192M
Impl. Move
±7.5%
Why consensus could be wrong
The Street may underestimate Ligand's ability to leverage its partnerships for revenue growth, especially given recent successes in their product pipeline.
Supporting evidence
The company has consistently beaten EPS estimates, indicating stronger operational performance than anticipated.
Options pricing suggests a larger expected move than historical averages, hinting at potential surprises.
Insider buying activity indicates confidence in the company's future performance.
Key risk
If revenue comes in below $53M, it could undermine confidence in Ligand's growth prospects.
Pre-commit to what would confirm each case.
The market is weighing the potential for Ligand to continue its streak of earnings surprises against the backdrop of revenue expectations.
Bull confirmed if
An EPS of $2.00 or higher would confirm the bull case, indicating continued strong performance.
Bear confirmed if
An EPS below $1.66 would support the bear case, raising concerns about profitability.
What the market is pricing for the move.
Implied Move
±7.91%
Historical Avg
±5.0%
The options market is pricing in a substantial move, indicating that traders expect significant volatility around the earnings report.
Options are pricing ±6.8% while LGND has averaged ±5.0% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
42.7%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$1.5M
5,000 sh
1 insider
Net
$1.5M
Net selling
Most Active Insiders· 6 open-market trades
$1.5M
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
116.13%
of float
Insider
2.34%
of float
Holders
550
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
3,100,996 sh · $909.4M
15.56%
4.7%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Ligand beats expectations, history suggests a potential stock increase of around 3.1%, confirming the company's strong growth narrative.
In line / cautious
If results are in line with expectations, the stock may see muted movement as investors await further guidance from management.
Miss
A miss on earnings could lead to a decline, with historical data suggesting a potential drop of around 3.1%.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
1 buy·0 sells
Members
1
House only
Est. Notional
$1,001.00–$15,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Recent Transactions
Oct 2, 2026 · @ $303.54
1,976 sh
$599,803.73
Oct 2, 2026 · @ $304.52
1,535 sh
$467,431.14
Oct 2, 2026 · @ $302.51
833 sh
$251,991.41
Oct 2, 2026 · @ $306.18
404 sh
$123,698.09
Oct 2, 2026 · @ $307.19
235 sh
$72,189.91
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Invesco Ltd.
1,201,644 sh · $352.4M
6.03%
45.9%
Vanguard Portfolio Management LLC
1,138,316 sh · $333.8M
5.71%
3.5%
Jupiter Topco LLC
1,040,578 sh · $305.2M
5.22%
100.0%
Vanguard Capital Management LLC
870,950 sh · $255.4M
4.37%
2.7%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net buying
Recent Transactions
Traded May 29, 2026 · disclosed Jun 8, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.